The latest update is out from 3SBio ( (HK:1530) ).
3SBio reported a strong financial performance for the year ending December 31, 2024, with a revenue increase of 16.5% to RMB9,108.0 million and a net profit rise of 34.9% to RMB2,090.3 million. The company’s robust growth in revenue and profitability highlights its solid market positioning and potential positive implications for stakeholders, as evidenced by the proposed final dividend of HKD25 cents per share.
More about 3SBio
3SBio is a biopharmaceutical company based in the Cayman Islands, focusing on the development and commercialization of pharmaceutical products. The company is involved in the healthcare industry, with a market focus on innovative therapies and treatments.
YTD Price Performance: 25.97%
Technical Sentiment Signal: Sell
Current Market Cap: $3.28B
Find detailed analytics on 1530 stock on TipRanks’ Stock Analysis page.